As of November 10, 2026, 4 holders' latest Schedule 13D or 13G filings report owning 5% or more of Adagene Inc. The largest reported stake is Peter Luo's, at 11.2%. 10 filings are on record since July 2, 2025 (Schedule 13D/A, June 8, 2026).
Sell to companies like Adagene Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Key facts
- · Reporting person: WuXi PharmaTech Healthcare Fund I L.P. · Sole voting: 0 · Shared voting: 2,891,594 · Sole dispositive: 0 · Shared dispositive: 2,891,594 · SCHEDULE 13G/A, 2026-08-14
- · Reporting person: Peter Luo · Sole voting: 6,242,998 · Shared voting: 0 · Sole dispositive: 2,230,998 · Shared dispositive: 434,248 · SCHEDULE 13D/A, 2026-06-08
- · Holder: WuXi PharmaTech Healthcare Fund I L.P. · Percent: 5.9% · SCHEDULE 13G/A
- · Holder: Janus Henderson Group Plc · Percent: 10.1% · SCHEDULE 13G
- · Holder: Chernett Jorey · Percent: 5.1% · SCHEDULE 13G
Adagene Inc. has 10 Schedule 13D or 13G filings on record since 2025-07-02. 4 holders' latest filing reports 5% or more of ordinary shares, par value us$0.0001 per share. Each figure below is the holder's own, as filed, with the filing linked.
Holders
| Holder | Percent | Shares | Latest | Event date |
|---|---|---|---|---|
| 11.2% | 6,242,998 | SCHEDULE 13D/A, 2026-06-08 | 2026-06-05 | |
| Janus Henderson Group Plc | 10.1% | 6,666,666 | SCHEDULE 13G, 2026-05-07 | 2026-04-30 |
| 8.7% | 5,095,351 | SCHEDULE 13G/A, 2026-01-29 | 2025-12-31 | |
| 5.1% | 2,389,060 | SCHEDULE 13G, 2026-03-18 | 2026-03-16 | |
| Panacea Venture Healthcare Fund II, L.P. | 3.8% | 2,250,000 | SCHEDULE 13G/A, 2025-11-14 | 2025-09-30 |
| WuXi PharmaTech Healthcare Fund I L.P. | 3.5% | 2,891,594 | SCHEDULE 13G/A, 2026-08-14 | 2026-06-30 |
| Fmr LLC | 0.9% | 473,949 | SCHEDULE 13G/A, 2025-07-02 | 2025-06-30 |
| General Atlantic Singapore Fund Pte. Ltd. | 0% | 0 | SCHEDULE 13G/A, 2026-02-17 | 2025-12-31 |
Holding shares or following this stake? See who's behind Adagene Inc. and the warning signs.
Free to see. No signup.
Keep reading
More on Adagene Inc. and the records around it.
Adagene Inc. elsewhere on the record
Companies that share a holder
- Panacea Venture Healthcare Fund II, L.P. also filed stake reports on 3 other companies: Atara Biotherapeutics, Inc. (May 2026), Connect Biopharma Holdings Limited (Apr 2026), CASI Pharmaceuticals, Inc. (Dec 2025)
- General Atlantic Singapore Fund Pte. Ltd. also filed stake reports on 10 other companies: Korsana Biosciences, Inc. (Sep 2026), dLocal Ltd (Aug 2026), Pharvaris N.V. (Aug 2026)
- Chernett Jorey also filed stake reports on 16 other companies: CVRx, Inc. (Oct 2026), WW INTERNATIONAL, INC. (Aug 2026), Neuronetics, Inc. (Aug 2026)
Watch Adagene Inc.
Get an email when Adagene Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Adagene Inc.?
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on Adagene Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Adagene Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
10 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Voting and dispositive power, as filed
| Reporting person | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Filing |
|---|---|---|---|---|---|
| Peter Luo | 6,242,998 | 0 | 2,230,998 | 434,248 | SCHEDULE 13D/A, 2026-06-08 |
| HAN 2020 Irrevocable Trust | 9,390,439 | 0 | 9,390,439 | 0 | SCHEDULE 13D/A, 2026-06-08 |
| WuXi PharmaTech Healthcare Fund I L.P. | 0 | 2,891,594 | 0 | 2,891,594 | SCHEDULE 13G/A, 2026-08-14 |
| WuXi AppTec Co., Ltd. | 0 | 2,891,594 | 0 | 2,891,594 | SCHEDULE 13G/A, 2026-08-14 |
The latest filing identifies Adagene Inc. by CUSIP 005329107 and gives its principal executive office as 4F, Building C14, No. 218, Xinghu Street, Suzhou Industrial Park, Suzhou, Jiangsu Province (SCHEDULE 13G/A, 2026-08-14).
What the percentages are based on
Row 11 of each Reporting Person's cover page to this Schedule 13G sets forth the percentages of the ordinary shares of the Issuer beneficially owned by such Reporting Person as of June 30, 2026 and is incorporated by reference.WuXi PharmaTech Healthcare Fund I L.P., SCHEDULE 13G/A, 2026-08-14
Purpose of Transaction (Item 4)
Peter Luo
On May 23, 2025, Mr. Luo received 191,667 ordinary shares from Great Han Fortune LP for the benefit of Peter Luo, and Xiaohong She received 23,333 ordinary shares from Great Han Fortune LP for the benefit of Xiaohong She. On May 23, 2025, Mr. Luo and Xiaohong She transferred 191,667 and 23,333 ordinary shares respectively to HAN 2020 Irrevocable Trust, for estate planning purpose. Due to the operation of the Concert Party Agreement dated December 14, 2020 among members of Peter Luo-Acting-in-Concert-Group, Peter Luo may be deemed to acquire or dispose additional beneficial ownership from time to time due to the acquisition or disposal of beneficial ownership by the members of Peter Luo-Acting-in-Concert-Group. The Reporting Persons acquired the ordinary shares reported herein for investment and estate planning purposes, in the ordinary course of business. Other than as disclosed in this Amendment, the Reporting Persons currently do not have any plans or proposals that would result in or relate to any of the transactions or changes listed in Items 4(a) through 4(j) of the Schedule 13D. Mr. Luo is the Chief Executive Officer and the Chairman of the Board of Directors of the Issuer. The Reporting Persons, including members of the Peter Luo-Acting-in-Concert-Group, may acquire additional ordinary shares in the ordinary course of business, including in connection with outstanding options or additional options to be granted by the Issuer to Mr. Luo and/or share repurchase plan …The first part of Item 4 of the SCHEDULE 13D/A filed 2026-06-08; the filing has the rest
Timeline
| Filed | Holder | Percent | Filing |
|---|---|---|---|
| 2025-07-02 | Fmr LLC | 0.9% | SCHEDULE 13G/A |
| 2025-11-14 | Panacea Venture Healthcare Fund II, L.P. | 3.8% | SCHEDULE 13G/A |
| 2025-11-14 | WuXi PharmaTech Healthcare Fund I L.P. | 7% | SCHEDULE 13G/A |
| 2026-01-29 | Smith Vincent C | 8.7% | SCHEDULE 13G/A |
| 2026-02-17 | General Atlantic Singapore Fund Pte. Ltd. | 0% | SCHEDULE 13G/A |
| 2026-03-18 | Chernett Jorey | 5.1% | SCHEDULE 13G |
| 2026-05-07 | Janus Henderson Group Plc | 10.1% | SCHEDULE 13G |
| 2026-05-15 | WuXi PharmaTech Healthcare Fund I L.P. | 5.9% | SCHEDULE 13G/A |
| 2026-06-08 | Peter Luo | 11.2% | SCHEDULE 13D/A |
| 2026-08-14 | WuXi PharmaTech Healthcare Fund I L.P. | 3.5% | SCHEDULE 13G/A |
Questions about who owns Adagene Inc.
Who owns Adagene Inc.?
On this page, 4 holders' latest ownership filings report 5% or more of Adagene Inc.: Peter Luo (11.2%, Schedule 13D/A, filed 2026-06-08), Janus Henderson Group Plc (10.1%, Schedule 13G, filed 2026-05-07), Smith Vincent C (8.7%, Schedule 13G/A, filed 2026-01-29) and Chernett Jorey (5.1%, Schedule 13G, filed 2026-03-18).
Who are the largest shareholders of Adagene Inc.?
By the share each holder's latest filing reports, the largest holders of Adagene Inc. on this page are Peter Luo (11.2%), Janus Henderson Group Plc (10.1%) and Smith Vincent C (8.7%).
When did Peter Luo buy into Adagene Inc.?
The filings give report dates, not purchase dates. The earliest filing from Peter Luo on this page is the Schedule 13D/A, filed 2026-06-08, reporting 11.2%. That earliest filing is itself an amendment, which updates an earlier report.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 10 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Tools for this story
Each opens in a new tab, filled in for Adagene Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.
Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.